Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial

We conducted an open label, dose escalation Phase 1 clinical trial of a tetravalent dengue DNA vaccine (TVDV) formulated in Vaxfectin(®) to assess safety and immunogenicity. A total of 40 dengue- and flavivirus-naive volunteers received either low-dose (1 mg) TVDV alone (N = 10, group 1), low-dose T...

Descripción completa

Detalles Bibliográficos
Autores principales: Danko, Janine R., Kochel, Tadeusz, Teneza-Mora, Nimfa, Luke, Thomas C., Raviprakash, Kanakatte, Sun, Peifang, Simmons, Monika, Moon, James E., De La Barrera, Rafael, Martinez, Luis Javier, Thomas, Stephen J., Kenney, Richard T., Smith, Larry, Porter, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930886/
https://www.ncbi.nlm.nih.gov/pubmed/29363446
http://dx.doi.org/10.4269/ajtmh.17-0416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930886/
https://www.ncbi.nlm.nih.gov/pubmed/29363446
http://dx.doi.org/10.4269/ajtmh.17-0416

Ejemplares similares